Published online before print March 6, 2006, doi: 10.1161/01.HYP.0000210554.61293.90
(Hypertension. 2006;47:803.)
© 2006 American Heart Association, Inc.
Brief Review |
Role of Circulating Karyocytes in the Initiation and Progression of Atherosclerosis
From the Departments of Nephrology and Hypertension (H.C., M.C.V., H.A.K., J.A.J., B.B.) and Vascular Medicine (M.C.V.), University Medical Center Utrecht, Utrecht, the Netherlands.
Correspondence to Branko Braam, Department of Nephrology and Hypertension F03.226, University Medical Center Utrecht, 3508 GA Utrecht, the Netherlands. E-mail bbraam{at}gmail.com
 |
Abstract |
|---|
 Top Abstract IntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
Cardiovascular disease is still hard to predict in an individual. The main focus in cardiovascular research has been on endothelial cells and vascular smooth muscle cells of the vessel wall and their interactions with the blood flow. Alterations in the properties of the blood have received a lot of attention in biochemical terms. Interestingly, alterations in the properties of circulating cells have received less attention. We propose that presence of 1 or more risk factors together with normal physiological stimuli induce redox-dependent changes in leukocyte gene transcription with pathophysiological responses. Thus, risk factors render leukocytes hypersensitive to normal stimuli. Risk factors can be subdivided into physical and chemical factors. Superimposed on physiological regulators of leukocyte function, these risk factors promote a cellular pro-oxidative state. Redox-sensitive transcription factors are activated, leading to responses involving inflammation, adhesion, migration, and additional reactive oxygen species generation. As a consequence, monitoring of individual gene expression signatures of these cells could well increase our understanding of the mechanisms by which leukocytes and, in particular, monocytes function. Furthermore, transcriptomes of these cells could be used to investigate the aggressiveness of the atherosclerotic process or to guide treatment in the patient with risk factors for atherosclerosis.
Key Words: gene expression • oxidative stress • atherosclerosis • leukocytes
|
Introduction |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
Despite great advances in our knowledge about initiation and progression of atherosclerosis, progress with respect to detection of individuals at risk for cardiovascular events is still limited. The availability of sophisticated biochemical assays to quickly and routinely screen soluble factors in large numbers of patients with atherosclerosis has led to an ever growing number of recognized cardiovascular risk factors. Nevertheless, methodology to asses the stage and aggressiveness of atherosclerotic disease is not available for individual subjects. Therefore, cardiovascular events are not predictable and, conversely, adequacy of treatment cannot be measured in an individual. This concern has been expressed in a call for new definitions and risk assessment strategies that proposes to classify vulnerable patients by criteria other than plaque vulnerability.1
Virchow’s triad (1856) describes changes in blood flow, the vessel wall, and properties of blood as a model for the pathogenesis of thrombosis. This triad may be applicable to the process of atherogenesis. The main focus in cardiovascular research has been on the vessel wall, in particular, endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) and their interactions with the blood flow. Alterations in the properties of the blood have received much attention in biochemical terms. Interestingly, alterations in the properties of circulating cells have received considerably less attention. In a lipid-feeding model, absence of endothelial intercellular adhesion molecule 1, P-selectin, CD18, or combinations of these molecules limited the size of atherosclerotic lesions but did not prevent atherogenesis,2,3 suggesting that activated ECs facilitate rather than initiate leukocyte infiltration and, thus, a more important role for circulating cells in atherogenesis. In this review, we discuss the pivotal role of the third component of the triad, that is, alterations in the properties of the components and the composition of blood, in particular, circulating karyocytes, in the initiation and progression of atherosclerosis. How are the leukocyte subpopulations and progenitor cells involved in the development and progression of atherosclerosis? Are leukocytes pivotal in the initiation of atherosclerosis or just secondary factors in atherogenesis? How is this related to the concept of dysfunctional stem cells?
We propose that circulating karyocytes form the driving force of the disease process. As such, circulating karyocytes can provide valuable information on the disease state of atherosclerosis. Because more and more information is appearing that all cells in the bloodstream with an active transcription apparatus can be relevant for the initiation and progression of atherosclerosis, the karyocyte is central. It also embodies that cells with highly different phases of differentiation are present, from stem cells to specialized lymphocytes. We consider the application of leukocyte gene expression in patients at risk for atherosclerosis for monitoring treatment of risk factors. In our view, correction of aberrant behavior of circulating karyocytes should be considered as a prime target in treatment of the cardiovascular patient.
|
Circulating Cells in the Initiation and Progression of Atherosclerosis |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
A variety of physicochemical stresses continuously endanger the integrity of the EC layer. Circulating karyocytes take part in maintenance and repair on the one hand but are also involved in lesion formation and progression on the other. We first consider regular maintenance and repair, with emphasis on progenitor cells, then the progression of microtrauma of the EC layer to more advanced lesions and plaque formation, and, finally, plaque rupture. For the evolution of microtrauma to plaque rupture we focus on leukocytes, in particular, monocytes and T lymphocytes. Additionally, the role of circulating karyocytes in EC maintenance and repair, with emphasis on vascular progenitor cells, is discussed.
|
Initiation of Damage to the Vascular Wall |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
ECs are constantly experiencing microinjury, which ultimately can lead to apoptosis and damage. Continuity of the EC layer is maintained by division of surrounding ECs and by incorporation of bone marrow–derived EC progenitor cells.4 Ongoing microinjury, facilitated by EC dysfunction and impaired endothelial regeneration and repair, eventually results in lesions evoking an injury response. Leukocyte adhesion and infiltration, the first histological sign of atherosclerosis, occurs as a response to injury. The inflammatory response particularly involves monocytes and T lymphocytes. Other than the occurrence of endothelial activation (increased expression of various leukocyte adhesion molecules), monocytes themselves can respond to physiological changes by increased adherence to ECs, as was observed in hypertension.5 Chemotaxis stimulated by monocytes leads to adhesion to ECs by the secretion of proinflammatory cytokines, such as transforming growth factor ß and tumor necrosis factor (TNF)
, thereby inducing M-colony–stimulating factor6 and adhesion molecules.7 T lymphocytes can modulate EC function and, hence, induce EC dysfunction: T lymphocyte–derived cytokines, such as TNF- and IFN-
, inhibit the anticoagulant properties of EC, induce the expression of adhesion molecules, and stimulate the formation of gaps between ECs, enhancing leukocyte adhesion and infiltration.8 These cytokines also enhance EC antigen presentation by upregulation of major histocompatibility complex molecules and enzymes involved in antigen peptide processing and loading,9 which can be counterbalanced by NO.10 Thus, EC may induce a T-cell response and, in turn, activation of T cells may result in EC dysfunction. |
Foam Cell Formation, Matrix Deposition, and Proliferation in the Vascular Wall |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
After the initial contact with the endothelium, monocytes infiltrate into the subendothelial layer. Once there, macrophage differentiation with concurrent induction of scavenger receptors facilitates uptake of oxidized low-density lipoprotein (oxLDL) leading to the formation of foam cells. The foam cells increase rapidly in number as they are trapped in the lesion by oxLDL. Even more oxLDL is formed via reactive oxygen species (ROS) produced by resident macrophages.11 T lymphocytes are attracted by inflammatory cytokines secreted by macrophages, such as inducible protein 10, monokine induced by IFN-
, and IFN-inducible -chemoattractant. Consequently, T lymphocytes are activated by oxLDL presented on major histocompatibility complex molecules in the lesion,12 which, in turn, causes the additional activation of macrophages, ECs, and VSMCs. Indeed, T-lymphocyte induction aggravates and T-cell inhibition attenuates the progression of atherogenesis in mice.13,14
During lesion formation, macrophages and T lymphocytes secrete growth factors, such as platelet-derived growth factor15 and VEGF,16 and cytokines, such as IFN-17 and interleukin (IL) 1,15 that stimulate VSMC migration into the intimal layer of the vessel wall. VSMCs, in turn, also secrete growth factors and synthesize extracellular matrix, which forms a fibrous cap, thus becoming an atherosclerotic plaque.15 In addition, monocytes and T lymphocytes secrete CC motif chemokine receptor, which mediates VSMC proliferation.18 To summarize, fibrous lesions grow as blood-derived inflammatory cells, and VSMCs promote the proatherosclerotic actions of each other.
|
Circulating Karyocytes and the Fate of Plaques |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
In advanced lesions, foam and vascular cells damaged by oxLDL11 become apoptotic or necrotic and leave a reservoir of extracellular lipid and cell debris at the core of the lesion.19 Plaque erosion, a frequent cause of serious coronary thrombotic events, may result from local production of inflammatory mediators or by cytotoxic attack by activated killer T cells, leading to EC death. Also, activated ECs may degrade the matrix membrane to which they adhere.20 Other lesions may develop into vulnerable plaques. These are characterized by a large lipid reservoir, filled with many inflammatory cells, and covered with a thin fibrous cap. Newly formed vessels inside the plaque, stimulated by angiogenic factors produced by inflammatory cells, are prone to hemorrhage. Such neovascularization may also cause massive growth of VSMCs and matrix expansion leading to a much larger lesion.20 These vessels may also provide a conduit for entry of even more inflammatory cells, increasing plaque instability.21 The fibrous cap is maintained in a delicate way with an important role of inflammatory cells. Proinflammatory cytokines, such as IFN-
, are able to inhibit matrix production by VSMCs. Moreover, inflammatory cells can secrete collagenases, such as matrix metalloproteinases, that break down matrix. The lesion edge, rich in foam cells, is, therefore, most prone to rupture. Thus, the fate of plaques is directed by inflammatory cells. |
Active Participation of Circulating Karyocytes in Atherogenesis |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
How could circulating cells become active players in damage? There are 2 plausible routes that are not mutually exclusive. A first option is that circulating cells, predominantly monocytes, become hypersensitive under the influence of physicochemical stimuli, including classical risk factors for atherosclerosis. Alternatively, circulating progenitor cells may become dysfunctional and fail to adequately participate in maintenance and repair of the vascular wall or even contribute to the formation of atherosclerotic lesions. Common to various injury pathways is the imbalance of NO and ROS. It is clear that NO can dampen many of the proinflammatory responses evoked by monocytes22 and ECs.23 Therefore, impaired NO production by ECs seems to be central in causing atherosclerosis.24
|
The Hypersensitive Leukocyte Hypothesis |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
Different types of leukocytes process a wide variety of physiological stimuli, which act together to establish an adequate immune response and clearance of dysfunctional cells. We propose that the presence of 1 or more risk factors together with normal physiological stimuli induce redox-dependent changes in leukocyte gene transcription with pathophysiological responses (Figure 1). Thus, risk factors render leukocytes hypersensitive to normal stimuli. This concept translates into differentially affected function for each circulating cell type. The overall effect is that all leukocytes become more sensitive and more readily adhere to and infiltrate into the vessel wall. Risk factors can be subdivided into physical and chemical factors. Superimposed on physiological regulators of leukocyte function, these risk factors promote a cellular pro-oxidative state. Redox-sensitive transcription factors are activated, leading to responses involving inflammation, adhesion, migration, and additional ROS generation (Figure 1).
|
|
Physical Factors |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
Circulating cells traveling in the bloodstream are subject to different mechanical forces: hydrostatic pressure, strain through deformation, and shear stress. Interestingly, limited information is available about the relationship between leukocyte cell function and mechanical forces. Intraluminal pressure may have diverse effects on monocytes and other circulating karyocytes. Hydrostatic pressure has been shown to increase the proliferatory response to phytohemagglutin A in monocytes,25 whereas amiloride-sensitive sodium channels in human B cells subjected to hydrostatic pressure are activated via the cytoskeleton.26 During cyclic strain, monocytes increase scavenger receptor class A and class B CD36 expression27 and adhesion via integrins and activation of calmodulin and inositol triphosphate.28 Furthermore, mechanical strain on monocytes induces c-fos and c-jun gene expression and activator protein (AP)-1 activity.29 Finally, because flow along the central axis of the vessel is higher than at the perimeter, circulating karyocytes sense differential flows and, thus, shear stress. The higher the flow, the greater the flow gradient across the cell surface, the higher the shear stress imposed on the cell. Very few studies have assessed the responses of monocytes or other leukocytes to shear stress. Leukocytes, including monocytes, display pseudopod (also called lamellipod) retraction in response to shear stress. Pseudopods are involved in adhesion and migration of monocytes. Pseudopod retraction is disturbed in endothelial NO synthase–/– mice and enhanced by cGMP analogues,30 which suggests an additional mechanism for increased adhesion in NO deficiency. Taken together, there is scattered evidence that monocytes demonstrate a variety of responses to mechanical forces; however, studies on interactions between the deranged physical forces in hypertension and enhanced renin–angiotensin system, ROS, and sympathetic nervous system activity on monocytes are not available.
|
Chemical Factors, in Particular, Angiotensin II, ROS, and Inflammation |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
Inappropriate activation of the renin–angiotensin system is evident in hypertension, uremia, and diabetes.31 Moreover, expression of the angiotensin II (Ang II) type 1 (AT1) receptor is increased in atherosclerotic lesions.32,33 Interestingly, we observed upregulation of the AT1 receptor in leukocytes of patients with essential hypertension.34 Downstream signaling pathways of the AT1 receptor can mediate numerous proatherogenic effects, in particular, enhanced expression of adhesion molecules, activation of inflammation via nuclear factor
B (NF-B) activation, and production of ROS.31 These proatherogenic effects occur in ECs and VSMCs and probably also in circulating karyocytes. Activation of AT1 receptor–dependent pathways may enhance adhesion by increased expression of macrophage antigen (Mac)-1 in granulocytes35 and migration in monocytes.36 Monocytes are very sensitive to Ang II stimulation, and Ang II favors differentiation of monocytes into dendritic cells, implying a role for Ang II in the invasion of these cells into the vascular wall.37 Moreover, cross-linking of AT1 receptor homodimers in monocytes, which is activated in hypertensive patients, enhances and prolongs signaling.38 In concordance, inhibition of Ang II generation or AT1 receptor cross-linking activity reduced the progression of atherosclerosis in mice.38 Finally, a recent study indicated that Ang II strongly induced vascular lesions via enhanced macrophage infiltration in wild-type mice that received bone marrow from apolipoprotein E–/– mice.39 Circulating karyocytes that have increased Ang II sensitivity are, thus, transformed into cells that are more prone to participate in adhesion, lesion formation, and inflammation, indicating their important role in atherogenesis.
There is also evidence that a shift in the NO/ROS balance toward oxidative stress can affect circulating karyocytes. Increased ROS production was observed in granulocytes in hypertensive rats35 and patients.40 All of the cell types in the vascular wall,41 as well as circulating karyocytes, such as neutrophils and monocytes, express reduced nicotinamide-adenine dinucleotide phosphate oxidase, a major source of ROS in cardiovascular disease. ROS-induced activation of NF-B, peroxidase proliferator–activated receptor , and other redox-sensitive transcription factors can mediate numerous effects in circulating karyocytes. Moreover, ROS can amplify the actions of IFN- and NF-B activation and enhance adhesion by upregulation of adhesion molecule Mac-1 on neutrophils.42 OxLDL is increased in overt cardiovascular disease and can enhance dendritic cell maturation.43 All in all, ROS and oxidative stress can render leukocytes hypersensitive, favoring the development of atherosclerotic lesions.
Inflammatory regulators, such as cytoplasmic repressor protein, TNF-, IL-1ß, IL-6, and IFN-, are elevated in cardiovascular disease. TNF- and IL-1ß, both strong inflammatory mediators secreted by activated macrophages, are potent inducers of NF-B. Additionally, IL-1ß can stimulate superoxide production directly by activating reduced nicotinamide-adenine dinucleotide phosphate oxidase in neutrophils and macrophages,44 whereas TNF- also activates c-jun. IL-6 has widespread actions in inflammation and mediates these effects via 2 distinct pathways, that is, Janus-activating kinase/signal transducer and activation of transcription and extracellular signal regulated kinase/mitogen- activated protein kinase signaling.45 Finally, the proinflammatory cytokine IFN- is important in the progression of inflammatory responses associated with cardiovascular disease.46–48 Evidence that IFN- promotes atherosclerosis is based on the observation that apolipoprotein E–/–, IFN- receptor double-knockout mice develop less atherosclerosis than apolipoprotein E–/–, IFN- receptor+/+ mice.49,50
|
Progenitor Cell Dysfunction and Dysbalance and Atherosclerosis |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
Subpopulations of mononuclear stem cells have the capacity not only to differentiate into hematopoietic cells also to differentiate into EC and VSMCs, myofibroblasts, cardiomyocytes, pancreatic cells, and so on, depending on the environment.12 Vascular progenitor cells can be isolated and cultured from peripheral blood, and many studies have demonstrated that endothelial progenitor cells (EPCs) contribute to neovascularization in response to limb or myocardial ischemia and to renal microvascular repair. The capacity of stem cells to develop into differentiated cell types may alter the course of disease.
As mentioned before, damage to the endothelium is repaired by replication of neighboring ECs and by incorporation of bone marrow–derived EPCs.51 Substantial evidence for a role in repair by EPCs has been derived from experiments applying hindlimb ischemia and studying repair by bone marrow–derived cells.51 Rookmaaker et al52 demonstrated that bone marrow–derived cells could also be found in the endothelial layer of renal vasculature of kidneys with glomerulonephritis. We studied the implications for vascular wall maintenance of the replacement of ECs by EPCs using a mathematical model.53 The competence of EPCs depends on the release from the bone marrow, homing to the site of injury,54 and the actual function, that is, proliferation and secretion of growth factors. Various conditions have been found to alter the release and angiogenesis of EPCs.55–57 It is becoming clear that number, function, and differentiation of progenitor cells can be affected by risk factors for atherosclerosis. For example, a decreased number and impaired function of EPCs have been reported in diabetes58,59 and in uremia,9,60 which may contribute to reduced endothelial regeneration and repair leading to vasculopathy. EPC numbers correlate with combined Framingham score and clinical outcome.61,62 Several reports have also suggested that vascular smooth muscle progenitor cells are present in the circulation, which may contribute to the development of atherosclerosis.54,63,64
Although mechanisms underlying the changes in vascular progenitor cell function are emerging,65 little is known about the influence of chemical factors, such as pressure and shear stress, on EPCs. Chemical factors, such as inflammation, particularly cytoplasmic repressor protein and hyperglycemia, have known detrimental effects on EPC survival and angiogenic capacity.66,67 On the other hand, Ang II stimulates EPC proliferation and EPC-induced angiogenesis,68,69 in contrast to the generally proatherogenic functions of Ang II. Because these experiments were performed with healthy donors, it is conceivable that Ang II signaling is dysregulated in cardiovascular patients. This idea is supported by the finding that angiotensin-converting enzyme inhibitors and AT1 receptor antagonists improve EPC numbers and function in patients with diabetes or coronary artery disease.70,71 In addition, Ang II may accelerate senescence via enhanced oxidative stress.72 Conversely, EPCs, or their pluripotent common precursor, may differentiate into cells with a vascular smooth muscle/myofibroblast phenotype that can have aggravating effects on plaque growth.73 It is, thus, clear that systemic factors also weaken repair mechanisms of the vessel wall.
|
Synchronized Hypersensitive Response in the Initiation and Progression of Atherosclerosis |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
Apparently, circulating karyocytes are affected by physicochemical stimuli just as much as EC, because they share the same environment. Moreover, ECs are known to be important mediators of inflammation by cytokine secretion and by enhancing leukocyte infiltration. However, apart from cell characteristics, the response to the environment could well be different. On the one hand, ECs are fixed to the vascular wall, with the consequence that neighboring cells modulate their response. On the other hand, circulating karyocytes, being exclusively exposed to the circulation, may be even more sensitive to systemic changes. All in all, atherosclerosis is most probably to be accompanied by synchronization in the hypersensitivity displayed by ECs and circulating karyocytes.
|
Circulating Karyocytes in Diagnosis and Treatment of (Pro)atherosclerotic Conditions |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
Few studies have addressed the possibility of monitoring circulating karyocytes or monocytes in particular to assess cardiovascular patients. Individual gene expression signatures of these cells could well increase our understanding of the mechanisms by which monocytes function. Furthermore, transcriptomes of these cells could be used to investigate the aggressiveness of the atherosclerotic process or to guide treatment in the patient with risk factors for atherosclerosis.
As mentioned previously, we propose that hypersensitive karyocytes are crucially involved in the development of atherosclerosis. Hypersensitivity or dysfunction of circulating cells may be reflected in aberrant gene expression profiles of these cells. Studying these transcriptomes, for example, using microarrays, may ideally allow determination of the stage of atherosclerotic disease and the tendency for disease progression in an individual. In addition, treatment efficacy may be evaluated in the same fashion. Which information is currently available that supports the feasibility to establish a diagnosis based on gene expression profiles? There are several examples where gene expression profiles offered accurate diagnosis and prognostic data. Studies in the oncology field are particularly successful because of the obvious availability of frozen tissue and the severity of the disease. The best-known examples are in breast cancer74 and lymphomas.75–77 Profiling easily accessible biological material, such as circulating cells, may allow for application of such an approach to many more fields. For lymphomas, this is obviously feasible, but gene expression profiles in other conditions that do not as clearly involve circulating cells have also been studied (Table). Others have also suggested that circulating cells could be useful in cardiovascular disease.78
|
We recently observed widespread changes in expression of inflammation-related genes in leukocytes from patients with essential hypertension. Microarray data were matched by conventional RT-PCR (Figure 2). This novel finding shows that essential hypertension is a complex systemic disease that involves an inflammatory response, partly by downregulation of anti-inflammatory IL receptors. Leukocytes also displayed differential expression of genes related to blood pressure control,34 in particular, increased expression of AT1 receptor. Strikingly, effective treatment of high blood pressure strongly reduced the number of modulated genes. This finding couples blood pressure to complex transcriptional changes in circulating karyocytes, which seems to be correctable.
|
To reach successful implementation of gene expression profiling of circulating cells for clinical use, several conditions are required. Standardization of blood withdrawal, processing, and storage in all of the participating medical centers is essential for comparability. The microarray technique can be subject to external factors that influence quality; a robust profiling technique is, therefore, needed. A selection of a set of atherosclerosis genes that facilitates use in the clinic would be preferable. Furthermore, microarray data should be presented and made publicly available, for which MIAME provides an excellent format.79 More importantly, microarray data should be interpreted together with clinical parameters. To be able to perform hierarchical clustering and classification strategies that incorporate these clinical data, both continuous and categorical parameters could be scaled to sensible numbers with ranges comparable to those of microarray gene expression ratios. We expect that the powerful combination of expression profiling and the use of circulating karyocytes will set off revolutionary changes in the treatment of cardiovascular patients.
|
Conclusions |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
In contrast to the general concept of atherosclerosis, circulating karyocytes are anything but passive bystanders that come into play only when ECs capture them. Circulating cells are sensitive to pressure or flow, endothelial dysfunction, and thrombogenic properties. The study of circulating karyocytes is, therefore, important in further understanding the mechanism of atherosclerosis.
|
Acknowledgments |
|---|
B.B. is a research fellow of the Royal Dutch Academy of Arts and Sciences. Studies mentioned in this report are supported by grant NS6013 from the Dutch Kidney Foundation. M.C.V. is supported by the Netherlands Organization for Scientific Research (NWO grant 016.036.041).
Received November 30, 2005; first decision December 18, 2005; accepted February 6, 2006.
|
References |
|---|
|
TopAbstractIntroductionCirculating Cells in the...Initiation of Damage to...Foam Cell Formation, Matrix...Circulating Karyocytes and the...Active Participation of...The Hypersensitive Leukocyte...Physical FactorsChemical Factors, in Particular,...Progenitor Cell Dysfunction and...Synchronized Hypersensitive...Circulating Karyocytes in...ConclusionsReferences |
|---|
1. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003; 108: 1772–1778.
2. Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2000; 191: 189–194.
3. Nageh MF, Sandberg ET, Marotti KR, Lin AH, Melchior EP, Bullard DC, Beaudet AL. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1997; 17: 1517–1520.
4. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964–967.
5. Dorffel Y, Franz S, Pruss A, Neumann G, Rohde W, Burmester GR, Scholze J. Preactivated monocytes from hypertensive patients as a factor for atherosclerosis? Atherosclerosis. 2001; 157: 151–160.[CrossRef][Medline] [Order article via Infotrieve]
6. Hong YH, Peng HB, La Fata V, Liao JK. Hydrogen peroxide-mediated transcriptional induction of macrophage colony-stimulating factor by TGF-ß1. J Immunol. 1997; 159: 2418–2423.
7. Chen YH, Yet SF, Perrella MA. Role of heme oxygenase–1 in the regulation of blood pressure and cardiac function. Exp Biol Med (Maywood). 2003; 228: 447–453.
8. Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev. 2003; 83: 1069–1112.
9. Choi J, Enis DR, Koh KP, Shiao SL, Pober JS. T lymphocyte-endothelial cell interactions. Annu Rev Immunol. 2004; 22: 683–709.[CrossRef][Medline] [Order article via Infotrieve]
10. Grimm M, Spiecker M, De Caterina R, Shin WS, Liao JK. Inhibition of major histocompatibility complex class II gene transcription by nitric oxide and antioxidants. J Biol Chem. 2002; 277: 26460–26467.
11. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med. 1997; 337: 408–416.
12. Waltner-Romen M, Falkensammer G, Rabl W, Wick G. A previously unrecognized site of local accumulation of mononuclear cells. The vascular-associated lymphoid tissue. J Histochem Cytochem. 1998; 46: 1347–1350.
13. Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariety J, Nicoletti A. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation. 2001; 104: 197–202.
14. Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, Hansson GK, Berne GP. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med. 2004; 199: 417–422.
15. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362: 801–809.[CrossRef][Medline] [Order article via Infotrieve]
16. Parenti A, Bellik L, Brogelli L, Filippi S, Ledda F. Endogenous VEGF-A is responsible for mitogenic effects of MCP-1 on vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2004; 286: H1978–H1984.
17. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999; 340: 115–126.
18. Haque NS, Fallon JT, Pan JJ, Taubman MB, Harpel PC. Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion. Blood. 2004; 103: 1296–1304.
19. Lusis AJ. Atherosclerosis. Nature. 2000; 407: 233–241.[CrossRef][Medline] [Order article via Infotrieve]
20. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–874.[CrossRef][Medline] [Order article via Infotrieve]
21. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo KM, Gillies S, Javaherian K, Folkman J. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A. 2003; 100: 4736–4741.
22. Corazzi T, Leone M, Roberti R, Del Soldato P, Gresele P. Effect of nitric oxide-donating agents on human monocyte cyclooxygenase-2. Biochem Biophys Res Commun. 2003; 311: 897–903.[CrossRef][Medline] [Order article via Infotrieve]
23. Braam B, de Roos R, Dijk A, Boer P, Post JA, Kemmeren PP, Holstege FC, Bluysen HA, Koomans HA. Nitric oxide donor induces temporal and dose-dependent reduction of gene expression in human endothelial cells. Am J Physiol Heart Circ Physiol. 2004; 287: H1977–H1986.
24. Rabelink TJ, Koomans HA. Endothelial function and the kidney. An emerging target for cardiovascular therapy. Drugs. 1997; 53 (suppl 1): 11–19.[CrossRef][Medline] [Order article via Infotrieve]
25. Eisenthal A, Gelfand A, Misonzhnik F, Trejo L, Schwartz I, Skornick Y, Lifschitz-Mercer B. Exposure of human peripheral blood mononuclear cells (PBMC) to hydrostatic pressure increases their proliferative response to phytohemagglutinin A (PHA) and anti-CD3 antibody. Immunol Invest. 1999; 28: 55–65.[Medline] [Order article via Infotrieve]
26. Achard JM, Bubien JK, Benos DJ, Warnock DG. Stretch modulates amiloride sensitivity and cation selectivity of sodium channels in human B lymphocytes. Am J Physiol. 1996; 270: C224–C234.[Medline] [Order article via Infotrieve]
27. Sakamoto H, Aikawa M, Hill CC, Weiss D, Taylor WR, Libby P, Lee RT. Biomechanical strain induces class a scavenger receptor expression in human monocyte/macrophages and THP-1 cells: a potential mechanism of increased atherosclerosis in hypertension. Circulation. 2001; 104: 109–114.
28. Ashida N, Takechi H, Kita T, Arai H. Vortex-mediated mechanical stress induces integrin-dependent cell adhesion mediated by inositol 1,4,5-trisphosphate-sensitive Ca2+ release in THP-1 cells. J Biol Chem. 2003; 278: 9327–9331.
29. Yang JH, Sakamoto H, Xu EC, Lee RT. Biomechanical regulation of human monocyte/macrophage molecular function. Am J Pathol. 2000; 156: 1797–1804.
30. Fukuda N, Nakayama M, Jian T, Satoh C, Nakayama T, Soma M, Izumi Y, Kanmatsuse K. Leukocyte angiotensin II levels inpatients with essential hypertension:relation to insulin resistance. Am J Hypertens. 2003; 16: 129–134.[CrossRef][Medline] [Order article via Infotrieve]
31. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003; 42: 1075–1081.
32. Song K, Shiota N, Takai S, Takashima H, Iwasaki H, Kim S, Miyazaki M. Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys. Atherosclerosis. 1998; 138: 171–182.[CrossRef][Medline] [Order article via Infotrieve]
33. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000; 101: 1372–1378.
34. Chon H, Gaillard CA, van der Meijden BB, Dijstelbloem HM, Kraaijenhagen RJ, van Leenen D, Holstege FC, Joles JA, Bluyssen HA, Koomans HA, Braam B. Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment. Hypertension. 2004; 43: 947–951.
35. Sela S, Mazor R, Amsalam M, Yagil C, Yagil Y, Kristal B. Primed polymorphonuclear leukocytes, oxidative stress, and inflammation antecede hypertension in the Sabra rat. Hypertension. 2004; 44: 764–769.
36. Kintscher U, Wakino S, Kim S, Fleck E, Hsueh WA, Law RE. Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension. 2001; 37: 587–593.
37. Nahmod KA, Vermeulen ME, Raiden S, Salamone G, Gamberale R, Fernandez-Calotti P, Alvarez A, Nahmod V, Giordano M, Geffner JR. Control of dendritic cell differentiation by angiotensin II. Faseb J. 2003; 17: 491–493.
38. Abdalla S, Lother H, Langer A, El Faramawy Y, Quitterer U. Factor XIIIA transglutaminase crosslinks AT(1) receptor dimers of monocytes at the onset of atherosclerosis. Cell. 2004; 119: 343–354.[CrossRef][Medline] [Order article via Infotrieve]
39. Nobuhiko A, Suganuma E, Babaev VR, Fogo A, Swift LL, Linton MF, Fazio S, Ichikawa I, Kon V. Angiotensin II amplifies macrophage-driven atherosclerosis. Arterioscler Thromb Vasc Biol. 2004; 24: 2143–2148.
40. Kristal B, Shurtz-Swirski R, Chezar J, Manaster J, Levy R, Shapiro G, Weissman I, Shasha SM, Sela S. Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension. Am J Hypertens. 1998; 11: 921–928.[CrossRef][Medline] [Order article via Infotrieve]
41. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003; 285: R277–R297.
42. Wang H, Nawata J, Kakudo N, Sugimura K, Suzuki J, Sakuma M, Ikeda J, Shirato K. The upregulation of ICAM-1 and P-selectin requires high blood pressure but not circulating renin-angiotensin system in vivo. J Hypertens. 2004; 22: 1323–1332.[CrossRef][Medline] [Order article via Infotrieve]
43. Alderman CJ, Bunyard PR, Chain BM, Foreman JC, Leake DS, Katz DR. Effects of oxidised low density lipoprotein on dendritic cells: a possible immunoregulatory component of the atherogenic micro-environment? Cardiovasc Res. 2002; 55: 806–819.
44. Yagisawa M, Yuo A, Kitagawa S, Yazaki Y, Togawa A, Takaku F. Stimulation and priming of human neutrophils by IL-1 and IL-1 ß: complete inhibition by IL-1 receptor antagonist and no interaction with other cytokines. Exp Hematol. 1995; 23: 603–608.[Medline]
[Order article via Infotrieve]
45. Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol. 2003; 149: 1–38.[Medline] [Order article via Infotrieve]
46. Juvonen J, Surcel HM, Satta J, Teppo AM, Bloigu A, Syrjala H, Airaksinen J, Leinonen M, Saikku P, Juvonen T. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1997; 17: 2843–2847.
47. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit. 2002; 8: RA5–R12.[Medline] [Order article via Infotrieve]
48. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21: 1876–1890.
49. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN- potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997; 99: 2752–2761.[Medline]
[Order article via Infotrieve]
50. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon- enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol. 2000; 157: 1819–1824.
51. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999; 85: 221–228.
52. Rookmaaker MB, Smits AM, Tolboom H, Van ’t Wout K, Martens AC, Goldschmeding R, Joles JA, Van Zonneveld AJ, Grone HJ, Rabelink TJ, Verhaar MC. Bone-marrow-derived cells contribute to glomerular endothelial repair in experimental glomerulonephritis. Am J Pathol. 2003; 163: 553–562.
53. Op den Buijs J, Musters M, Verrips T, Post JA, Braam B, van Riel N. Mathematical modeling of vascular endothelial layer maintenance: the role of endothelial cell division, progenitor cell homing, and telomere shortening. Am J Physiol Heart Circ Physiol. 2004; 287: H2651–H2658.
54. Shimizu K, Sugiyama S, Aikawa M, Fukumoto Y, Rabkin E, Libby P, Mitchell RN. Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathy. Nat Med. 2001; 7: 738–741.[CrossRef][Medline] [Order article via Infotrieve]
55. Hristov M, Erl W, Linder S, Weber PC. Apoptotic bodies from endothelial cells enhance the number and initiate the differentiation of human endothelial progenitor cells in vitro. Blood. 2004; 104: 2761–2766.
56. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol. 2003; 23: 1185–1189.
57. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10: 858–864.[CrossRef][Medline] [Order article via Infotrieve]
58. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002; 106: 2781–2786.
59. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes. 2004; 53: 195–199.
60. de Groot K, Bahlmann FH, Sowa J, Koenig J, Menne J, Haller H, Fliser D. Uremia causes endothelial progenitor cell deficiency. Kidney Int. 2004; 66: 641–646.[CrossRef][Medline] [Order article via Infotrieve]
61. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348: 593–600.
62. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005; 353: 999–1007.
63. Hillebrands JL, Klatter FA, van den Hurk BM, Popa ER, Nieuwenhuis P, Rozing J. Origin of neointimal endothelium and -actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest. 2001; 107: 1411–1422.[CrossRef][Medline]
[Order article via Infotrieve]
64. Simper D, Wang S, Deb A, Holmes D, McGregor C, Frantz R, Kushwaha SS, Caplice NM. Endothelial progenitor cells are decreased in blood of cardiac allograft patients with vasculopathy and endothelial cells of noncardiac origin are enriched in transplant atherosclerosis. Circulation. 2003; 108: 143–149.
65. Dimmeler S, Zeiher AM. Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis? J Mol Med. 2004; 82: 671–677.[CrossRef][Medline] [Order article via Infotrieve]
66. George J, Goldstein E, Abashidze S, Deutsch V, Shmilovich H, Finkelstein A, Herz I, Miller H, Keren G. Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation. Eur Heart J. 2004; 25: 1003–1008.
67. Krankel N, Adams V, Linke A, Gielen S, Erbs S, Lenk K, Schuler G, Hambrecht R. Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. Arterioscler Thromb Vasc Biol. 2005; 25: 698–703.
68. Rodgers KE, Xiong S, Steer R, diZerega GS. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. 2000; 18: 287–294.[CrossRef][Medline] [Order article via Infotrieve]
69. Imanishi T, Hano T, Nishio I. Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. Hypertens Res. 2004; 27: 101–108.[CrossRef][Medline] [Order article via Infotrieve]
70. Min TQ, Zhu CJ, Xiang WX, Hui ZJ, Peng SY. Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2004; 18: 203–209.[CrossRef][Medline] [Order article via Infotrieve]
71. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension. 2005; 45: 526–529.
72. Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens. 2005; 23: 97–104.[CrossRef][Medline] [Order article via Infotrieve]
73. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med. 2002; 8: 403–409.[CrossRef][Medline] [Order article via Infotrieve]
74. van ’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415: 530–536.[CrossRef][Medline] [Order article via Infotrieve]
75. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999; 286: 531–537.
76. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503–511.[CrossRef][Medline] [Order article via Infotrieve]
77. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 1937–1947.
78. Pravenec M, Wallace C, Aitman TJ, Kurtz TW. Gene expression profiling in hypertension research: a critical perspective. Hypertension. 2003; 41: 3–8.
79. Brazma A, Vilo J. Gene expression data analysis. Microbes Infect. 2001; 3: 823–829.[CrossRef][Medline] [Order article via Infotrieve]
80. Rus V, Chen H, Zernetkina V, Magder LS, Mathai S, Hochberg MC, Via CS. Gene expression profiling in peripheral blood mononuclear cells from lupus patients with active and inactive disease. Clin Immunol. 2004; 112: 231–234.[CrossRef][Medline] [Order article via Infotrieve]
81. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003; 197: 711–723.
82. Bomprezzi R, Ringner M, Kim S, Bittner ML, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer PS, Martin R, McFarland HF, Trent JM. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet. 2003; 12: 2191–2199.
83. Olsen N, Sokka T, Seehorn CL, Kraft B, Maas K, Moore J, Aune TM. A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells. Ann Rheum Dis. 2004; 63: 1387–1392.
84. Jarvis JN, Dozmorov I, Jiang K, Frank MB, Szodoray P, Alex P, Centola M. Novel approaches to gene expression analysis of active polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther. 2004; 6: R15–R32.[CrossRef][Medline] [Order article via Infotrieve]
85. Achiron A, Gurevich M, Magalashvili D, Kishner I, Dolev M, Mandel M. Understanding autoimmune mechanisms in multiple sclerosis using gene expression microarrays: treatment effect and cytokine-related pathways. Clin Dev Immunol. 2004; 11: 299–305.[CrossRef][Medline] [Order article via Infotrieve]
86. Flechner SM, Kurian SM, Head SR, Sharp SM, Whisenant TC, Zhang J, Chismar JD, Horvath S, Mondala T, Gilmartin T, Cook DJ, Kay SA, Walker JR, Salomon DR. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant. 2004; 4: 1475–1489.[CrossRef][Medline] [Order article via Infotrieve]
87. Preston GA, Waga I, Alcorta DA, Sasai H, Munger WE, Sullivan P, Phillips B, Jennette JC, Falk RJ. Gene expression profiles of circulating leukocytes correlate with renal disease activity in IgA nephropathy. Kidney Int. 2004; 65: 420–430.[CrossRef][Medline] [Order article via Infotrieve]
88. Jison ML, Munson PJ, Barb JJ, Suffredini AF, Talwar S, Logun C, Raghavachari N, Beigel JH, Shelhamer JH, Danner RL, Gladwin MT. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004; 104: 270–280.
89. Tang Y, Lu A, Aronow BJ, Sharp FR. Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease. Ann Neurol. 2001; 50: 699–707.[CrossRef][Medline] [Order article via Infotrieve]
90. Bull TM, Coldren CD, Moore M, Sotto-Santiago SM, Pham DV, Nana-Sinkam SP, Voelkel NF, Geraci MW. Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004; 170: 911–919.
91. Lampe JW, Stepaniants SB, Mao M, Radich JP, Dai H, Linsley PS, Friend SH, Potter JD. Signatures of environmental exposures using peripheral leukocyte gene expression: tobacco smoke. Cancer Epidemiol Biomarkers Prev. 2004; 13: 445–453.
This article has been cited by other articles:
 |
|
 |
|
  J. A. Joles Statins and small GTPases: Koch's postulates and chronic kidney disease Nephrol. Dial. Transplant., February 1, 2008; 23(2): 433 - 438. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||